Open AccessUse of Factor VIIa and Anti-inhibitor Coagulant Complex in Pediatric Cardiac Surgery Patients
Author(s) -
Rachel B Carroll,
Hania Zaki,
Courtney McCracken,
Janet Figueroa,
Nina A. Guzzetta
Publication year - 2020
Publication title -
the journal of pediatric pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 15
eISSN - 2331-348X
pISSN - 1551-6776
DOI - 10.5863/1551-6776-25.6.540
Subject(s) - medicine , recombinant factor viia , cardiac surgery , cardiopulmonary bypass , thrombus , blood product , anesthesia , adverse effect , surgery , anticoagulant , prothrombin complex concentrate , activated clotting time , warfarin , atrial fibrillation
Postoperative bleeding is a common cause of morbidity and mortality in cardiac patients who undergo cardiopulmonary bypass (CPB). Pediatric patients are especially at risk for adverse effects of surgery and CPB on the coagulation system. This can result in bleeding, transfusions, and poor outcomes. Excessive bleeding unresponsive to blood products can warrant the off-label use of recombinant activated clotting factor VIIa (rFVIIa) and/or anti-inhibitor coagulant complex (FEIBA). Several studies have shown the utility in these agents off-label in patients who have undergone cardiac bypass surgery with acute bleeding episodes that are refractory to blood products. However, data regarding use of these agents in pediatrics are sparse. The purpose of this study is to report the use of rFVIIa and FEIBA in pediatric cardiac surgery patients in our institution.